VERTEX PHARMACEUTICALS INC. - Weekly - Technical analysis published on 08/19/2022 (GMT)
- 273
- 0
Click here for a new analysis!
- Timeframe : Weekly
- - Analysis generated on
- Status : TARGET REACHED
Summary of the analysis
Additional analysis
Quotes
The VERTEX PHARMACEUTICALS INC. rating is 299.04 USD. The price registered an increase of +1.54% over 5 days with the lowest point at 293.71 USD and the highest point at 305.95 USD. The deviation from the price is +1.81% for the low point and -2.26% for the high point.A bearish opening was detected by the Central Gaps scanner. Sellers are trying to impose a bearish trend in the very short term.
Bearish opening
Type : Bearish
Timeframe : Openning
Here is a more detailed summary of the historical variations registered by VERTEX PHARMACEUTICALS INC.:
Near a new HIGH record (5 years)
Type : Bullish
Timeframe : Weekly
Near a new HIGH record (1 year)
Type : Bullish
Timeframe : Weekly
Near a new HIGH record (1st january)
Type : Bullish
Timeframe : Weekly
Near a new HIGH record (1 month)
Type : Bullish
Timeframe : Weekly
Technical
A technical analysis in Weekly of this VERTEX PHARMACEUTICALS INC. chart shows a strongly bullish trend. 92.86% of the signals given by moving averages are bullish. This strongly bullish trend is supported by the strong bullish signals given by short-term moving averages. There is no crossing of moving average by the price or crossing of moving averages between themselves.
In fact, according to the parameters integrated into the Central Analyzer system, 15 technical indicators out of 18 analysed are currently bullish. But beware of excesses. The Central Indicators scanner currently detects this:
CCI indicator is overbought : over 100
Type : Neutral
Timeframe : Weekly
Williams %R indicator is overbought : over -20
Type : Neutral
Timeframe : Weekly
MACD crosses UP its Moving Average
Type : Bullish
Timeframe : Weekly
Price is back over the pivot point
Type : Bullish
Timeframe : Weekly
An analysis of the price chart with the Central Patterns scanner (detector of chart patterns and resistances and supports) shows a result that can have an impact on the price change:
Resistance of channel is broken
Type : Bullish
Timeframe : Weekly
The Central Candlesticks scanner which studies Japanese candlesticks did not detect anything.
S3 | S2 | S1 | Price | R1 | |
---|---|---|---|---|---|
ProTrendLines | 207.01 | 234.96 | 290.93 | 299.04 | 303.10 |
Change (%) | -30.78% | -21.43% | -2.71% | - | +1.36% |
Change | -92.03 | -64.08 | -8.11 | - | +4.06 |
Level | Intermediate | Intermediate | Major | - | Major |
Pivot points can also be used to set your price objectives. Here is the price situation in relation to pivot points:
Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
---|---|---|---|---|---|---|---|
Standard | 285.86 | 288.99 | 294.01 | 297.14 | 302.16 | 305.29 | 310.31 |
Camarilla | 296.80 | 297.55 | 298.29 | 299.04 | 299.79 | 300.53 | 301.28 |
Woodie | 286.82 | 289.46 | 294.97 | 297.61 | 303.12 | 305.76 | 311.27 |
Fibonacci | 288.99 | 292.10 | 294.02 | 297.14 | 300.25 | 302.17 | 305.29 |
Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
---|---|---|---|---|---|---|---|
Standard | 275.03 | 281.84 | 288.18 | 294.99 | 301.33 | 308.14 | 314.48 |
Camarilla | 290.90 | 292.11 | 293.32 | 294.52 | 295.73 | 296.93 | 298.14 |
Woodie | 274.80 | 281.72 | 287.95 | 294.87 | 301.10 | 308.02 | 314.25 |
Fibonacci | 281.84 | 286.86 | 289.97 | 294.99 | 300.01 | 303.12 | 308.14 |
Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
---|---|---|---|---|---|---|---|
Standard | 250.57 | 263.11 | 271.76 | 284.30 | 292.95 | 305.49 | 314.14 |
Camarilla | 274.58 | 276.53 | 278.47 | 280.41 | 282.35 | 284.30 | 286.24 |
Woodie | 248.63 | 262.14 | 269.82 | 283.33 | 291.01 | 304.52 | 312.20 |
Fibonacci | 263.11 | 271.21 | 276.21 | 284.30 | 292.40 | 297.40 | 305.49 |
Numerical data
The following is the status of the technical indicators and moving averages at the time of publication of this technical analysis:
RSI (14): | 64.27 | |
MACD (12,26,9): | 14.5400 | |
Directional Movement: | 12.09 | |
AROON (14): | 100.00 | |
DEMA (21): | 294.98 | |
Parabolic SAR (0,02-0,02-0,2): | 254.83 | |
Elder Ray (13): | 15.89 | |
Super Trend (3,10): | 249.27 | |
Zig ZAG (10): | 299.04 | |
VORTEX (21): | 1.1100 | |
Stochastique (14,3,5): | 88.20 | |
TEMA (21): | 297.42 | |
Williams %R (14): | -11.01 | |
Chande Momentum Oscillator (20): | 25.31 | |
Repulse (5,40,3): | 3.8500 | |
ROCnROLL: | 1 | |
TRIX (15,9): | 0.8600 | |
Courbe Coppock: | 19.36 |
MA7: | 298.25 | |
MA20: | 289.10 | |
MA50: | 282.70 | |
MA100: | 274.85 | |
MAexp7: | 289.31 | |
MAexp20: | 275.36 | |
MAexp50: | 252.33 | |
MAexp100: | 237.04 | |
Price / MA7: | +0.26% | |
Price / MA20: | +3.44% | |
Price / MA50: | +5.78% | |
Price / MA100: | +8.80% | |
Price / MAexp7: | +3.36% | |
Price / MAexp20: | +8.60% | |
Price / MAexp50: | +18.51% | |
Price / MAexp100: | +26.16% |
News
Don't forget to follow the news on VERTEX PHARMACEUTICALS INC.. At the time of publication of this analysis, the latest news was as follows:
- Vertex Reports Second Quarter 2022 Financial Results
- Vertex Advances VX-548 in Acute and Neuropathic Pain
- Vertex to Announce Second Quarter 2022 Financial Results on August 4
- Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
- Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
Add a comment
Comments
0 comments on the analysis VERTEX PHARMACEUTICALS INC. - Weekly